Kamada Ltd. KMDA.TA Stock
Kamada Ltd. Price Chart
Kamada Ltd. KMDA.TA Financial and Trading Overview
Kamada Ltd. stock price | 1916 ILA |
Previous Close | 2063 ILA |
Open | 2040 ILA |
Bid | 2077 ILA x N/A |
Ask | 2080 ILA x N/A |
Day's Range | 1999 - 2080 ILA |
52 Week Range | 1309 - 2200 ILA |
Volume | 14.76K ILA |
Avg. Volume | 38.75K ILA |
Market Cap | 117.77B ILA |
Beta (5Y Monthly) | 0.172207 |
PE Ratio (TTM) | 6403.125 |
EPS (TTM) | 0.56 ILA |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
KMDA.TA Valuation Measures
Enterprise Value | 933.97M ILA |
Trailing P/E | 6403.125 |
Forward P/E | 9757.144 |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 807.66656 |
Price/Book (mrq) | 525.11536 |
Enterprise Value/Revenue | 6.405 |
Enterprise Value/EBITDA | 44.752 |
Trading Information
Kamada Ltd. Stock Price History
Beta (5Y Monthly) | 0.172207 |
52-Week Change | N/A |
S&P500 52-Week Change | N/A |
52 Week High | 2200 ILA |
52 Week Low | 1309 ILA |
50-Day Moving Average | 1992.6 ILA |
200-Day Moving Average | 1758.94 ILA |
KMDA.TA Share Statistics
Avg. Volume (3 month) | 38.75K ILA |
Avg. Daily Volume (10-Days) | 16.96K ILA |
Shares Outstanding | 57.47M |
Float | 21.16M |
Short Ratio | N/A |
% Held by Insiders | 13.80% |
% Held by Institutions | 34.75% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | June 30, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 2.35% |
Operating Margin (ttm) | 6.51% |
Gross Margin | 37.33% |
EBITDA Margin | 14.31% |
Management Effectiveness
Return on Assets (ttm) | 1.91% |
Return on Equity (ttm) | 1.96% |
Income Statement
Revenue (ttm) | 145.81M ILA |
Revenue Per Share (ttm) | 3.22 ILA |
Quarterly Revenue Growth (yoy) | 58.69% |
Gross Profit (ttm) | 46.7M ILA |
EBITDA | 20.87M ILA |
Net Income Avi to Common (ttm) | 3.43M ILA |
Diluted EPS (ttm) | 0.32 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 21.79M ILA |
Total Cash Per Share (mrq) | 0.48 ILA |
Total Debt (mrq) | 21.22M ILA |
Total Debt/Equity (mrq) | 12.01 ILA |
Current Ratio (mrq) | 1.97 |
Book Value Per Share (mrq) | 3.902 |
Cash Flow Statement
Operating Cash Flow (ttm) | 11.22M ILA |
Levered Free Cash Flow (ttm) | 11.32M ILA |
Profile of Kamada Ltd.
Country | Israel |
State | N/A |
City | Rehovot |
Address | 2 Holzman Street |
ZIP | 7670402 |
Phone | 972 8 940 6472 |
Website | https://www.kamada.com |
Industry | Drug Manufacturers-Specialty & Generic |
Sector(s) | Healthcare |
Full Time Employees | 380 |
Kamada Ltd., together with its subsidiaries, provides plasma-derived protein therapeutics. It operates in two segments, Proprietary Products and Distribution. The company offers WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; VARIZIG for post exposure prophylaxis of varicella; and GLASSIA for intravenous AATD. It also provides KamRho (D) IM for prophylaxis of hemolytic disease of newborns; KamRho (D) IV for immune thermobocytopunic purpura; and snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus. In addition, the company distributes BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN for Allergic rhinitis and Urticaria; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for cytomegalovirus virus; RUCONEST for angioedema attacks; heparin sodium injection for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. Further, it offers IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; and ELIGARD for prostate cancer. The company markets its products through strategic partners in the United States, as well as through distributors internationally. It has strategic partnerships with Takeda Pharmaceuticals Company Limited; PARI GmbH; and Kedrion Biopharma. Kamada Ltd. was incorporated in 1990 and is headquartered in Rehovot, Israel.
Q&A For Kamada Ltd. Stock
What is a current KMDA.TA stock price?
Kamada Ltd. KMDA.TA stock price today per share is 1916 ILA.
How to purchase Kamada Ltd. stock?
You can buy KMDA.TA shares on the Tel Aviv exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Kamada Ltd.?
The stock symbol or ticker of Kamada Ltd. is KMDA.TA.
Which industry does the Kamada Ltd. company belong to?
The Kamada Ltd. industry is Drug Manufacturers-Specialty & Generic.
How many shares does Kamada Ltd. have in circulation?
The max supply of Kamada Ltd. shares is 581.69K.
What is Kamada Ltd. Price to Earnings Ratio (PE Ratio)?
Kamada Ltd. PE Ratio is 34.21428700 now.
What was Kamada Ltd. earnings per share over the trailing 12 months (TTM)?
Kamada Ltd. EPS is 0.56 ILA over the trailing 12 months.
Which sector does the Kamada Ltd. company belong to?
The Kamada Ltd. sector is Healthcare.
Kamada Ltd. KMDA.TA included in indexes
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
---|
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
---|---|---|---|---|---|---|---|
{{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
NASDAQ Developed ex US SC NTR G NQDMXUSSCGBPN | 1704.47 GBP 2179.91 USD |
0
|
— — | 1704.47 GBP 2179.91 USD | 1704.47 GBP 2179.91 USD | — - | — — |
- {{ link.label }} {{link}}